Kalaris Therapeutics

Yahoo Finance • 3 months ago

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent re... Full story

Yahoo Finance • 7 months ago

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development... Full story

Yahoo Finance • 8 months ago

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the re... Full story

Yahoo Finance • 8 months ago

Piper Sandler assumes coverage of Kalaris stock with Neutral rating

Investing.com - Piper Sandler has initiated coverage of Kalaris (NASDAQ:KLRS) with a Neutral rating and a $3.00 price target. The micro-cap biotech company, currently valued at $48 million, has seen its shares decline by roughly 78% over t... Full story

Yahoo Finance • 9 months ago

Kalaris stock rating reiterated at Outperform by William Blair

Investing.com - William Blair has reiterated an Outperform rating on Kalaris (NASDAQ:KLRS), maintaining its positive outlook on the biopharmaceutical company focused on treating neovascular retinal diseases. The company, currently valued a... Full story

Yahoo Finance • 10 months ago

Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities

BOSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would b... Full story

Yahoo Finance • 10 months ago

Kalaris to Participate at Stifel Ophthalmology Forum

PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal... Full story

Yahoo Finance • 11 months ago

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the reti... Full story

Yahoo Finance • 12 months ago

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

PALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retina... Full story